Year: 2025
Type: article
Abstract: The study titled “Oncolytic virus VG161 in refractory hepatocellular carcinoma” presents a promising advancement in third-line therapy for advanced hepatocellular carcinoma (HCC). VG161, derived from an oncolytic herpes simplex virus, is engineered to express interleukin (IL)-12, IL-15, IL-15R, and a fusion protein that blocks the programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) pathway. In the multicenter phase 1 clinical trial, VG161 exhibited both strong efficacy and safety. This paper summarizes the study’s findings, discusses potential limitations, and proposes directions for future research.
Source: Hepatoma Research
Authors: Yunxin Hong, Xiaohong Cui, Renan Chang, Shishengnan Song, Lu Qian, Huilin Zhu, Letao Tan, Zixu Hong, Mingxun Yi, Yi Zhou, Haijian Zhang
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: diamond
Awards: G2362382504, G7761459441
OpenAlex ID: W4415980415